Glenmark Readies Push For SGLT2i With Torrent Deal, More In Store

Glenmark is pressing ahead with plans to widen market opportunities for remogliflozin in India. Its co-marketing alliance with Torrent is potentially the first among similar deals anticipated for the novel sodium glucose co-transporter-2 (SGLT2) inhibitor in a competitive segment.

Diabetes
Glenmark has firmed up a deal with Torrent for remogliflozin

Glenmark Pharmaceuticals Ltd. has sealed a licensing deal with peer Torrent Pharmaceuticals Ltd. for its novel sodium glucose co-transporter-2 (SGLT2) inhibitor, remogliflozin etabonate, as it pursues rapid market expansion for the diabetes therapy in India.

This is potentially the first of such alliances as Glenmark seeks to shake up the SGLT2 inhibitor segment, emulating what...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.